IN THE CLAIMS

This listing of claims replaces all previous versions and listings of claims in this application.

Listing of Claims

Claims 1-18 (cancelled).

Claim 19 (Original). A device used for medical procedures, comprising:

a medical device having a surface modified by a surface treatment process comprising:

exposing the device to a reactive gas and plasma energy to create a plasma deposited surface on the device; and

quenching the device with the reactive gas.

Claim 20 (Original). The device of claim 19, wherein the surface treatment process further comprises, prior to the exposing step, the step of exposing the device to air and plasma energy to clean the surface.

Claim 21 (Original). The device of claim 19, wherein the surface treatment process further comprises the steps of:

placing the device in a plasma chamber; and

infusing air into the plasma chamber, wherein the placing and infusing steps occur prior to exposing the device to plasma energy.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 | Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com Claim 22 (Original). The device of claim 21, wherein the quenching step in the surface treatment process includes infusing the plasma chamber with the reactive gas.

Claim 23 (Original). The device of claim 19, wherein the reactive gas in the surface treatment process is a polymerizable gas.

Claim 24 (Original). The device of claim 19, wherein the surface treatment process further comprises the step of:

exposing the device, after the quenching step, to a surface graft material to bind the surface graft material to the plasma deposited surface.

Claim 25 (Original). The device of claim 24, wherein the surface graft material is acrylic acid.

Claim 26 (Original). The device of claim 24, wherein the surface graft material is acrylamide.

Claim 27 (Original). The device of claim 24, wherein the surface treatment process further comprises the step of:

coupling a surface reactant species to the surface after the surface graft exposure step.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLL

1300 l Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com Claim 28 (Original). The device of claim 27, wherein the surface reactant species is

heparin.

Claim 29 (Original). The device of claim 27, wherein the surface reactant species is

collagen.

Claim 30 (Original). The device of claim 27, wherein the surface reactant species is

PHB.

Claim 31 (Original). The device of claim 24, wherein in the surface treatment process

the device is exposed to the surface graft material without a plasma activation step

occurring after the quenching step.

Claim 32 (Original). The device of claim 31, wherein the device is exposed to the

surface graft material over 12 hours after the quenching step.

Claim 33 (Original). The device of claim 31, wherein the device is exposed to the

surface graft material over 48 hours after the quenching step.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

5